Systemic treatment of severe forms of acne: experience of using Isotretinoin in the Russian Federation


Cite item

Full Text

Abstract

The article presents the results of a large-scale Russian program of the follow-up and treatment of acne patients with Isotretinoin (Roaccutane). The analysis of the results included information about 1,349 acne patients. In 71% of patients, the therapy was initiated at the dose of 0.5-1.0 mg/kg of the body weight. The average duration of treatment was 21.5±0.16 weeks while the average course dose was 119.9±0.8 mg/kg of the body weight. As many as 96% of patients achieved a positive result; women demonstrated a higher improvement rate than men. On the whole, Roaccutane was well-tolerated while adverse effects included dry lips (43.4%), dry skin in different areas (12.45%), retinoid dermatitis (6.45%), epistaxis (2.45%), conjunctivitis (1.41%) and hoarseness (0.22%). The Russian experience of using Roaccutane confirmed high efficacy of the systemic therapy for severe forms of acne.

About the authors

A A KUBANOVA

State Research Center of Dermatovenereology and Cosmetology Ministry of Healthcare of the Russian Federation

д.м.н., профессор, академик РАМН, директор

YE R ARAVIYSKAYA

Pavlov State Medical University of St. Peterburg

Email: arelenar@mail.ru
д.м.н., профессор кафедры дерматовенерологии с клиникой

YE V SOKOLOVSKY

Pavlov State Medical University of St. Peterburg

д.м.н., профессор, заведующий кафедрой с клиникой

YE K DVOROVA

Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» under the Russian Academy of Medical Sciences

ведущий инженер, отдел информационных технологий

YE I FADEYEVA

F. Hoffmann-La Roche Ltd. Representative office in Russia

медицинский менеджер

References

  1. Кубанова А.А., Самсонов В.А., Забненкова О.В. Современные особенности патогенеза и терапии акне. Вестн дерматол и венерол 2003; 1: 9-16
  2. Масюкова С.А., Ахтямов С.Н. Акне: проблема и решение. Consilium Medicum. Дерматология 2002; 4(5): 217-223
  3. Руководство по дерматокосметологии. Под ред. Аравийской Е.Р и Соколовского Е.В. СПб.: Фолиант, 2008. 632 с
  4. Кохан М.М., Шабардина О.В. Фармакоэкономическая оценка терапии тяжелых форм акне. http://www.dermatology.ru/ collections/farmakoekonomicheskaya-otsenka-terapii-tyazhelykh-form-akne
  5. Шабардина О.В., Кохан М.М. Фармакоэкономический анализ различных методов терапии тяжелых форм акне. 2008. http://www.dermatology.ru/collections/ farmakoekonomicheskiianaliz-razlichnykh-metodov-terapii-tyazhelykhform-akne
  6. McConnell R.C., Fleischer A.B., Williford P.M., Feldman S.R. Most topical tretinoin treatment isfor acne vulgaris through the age of 44 years: an-analysis of the National Ambulatory Medical Care Survey, 1990-1994. J Am Acad Dermatol 1998; 38: 221-226
  7. Webster G.F. Acne vulgaris. BMJ 2002; 31: 475-479
  8. Perkins A.C., Maglione J., Hillebrand G.G., Miyamoto K., Kimball A.B. Acne vulgaris in women: prevalence across the life span. J Womens Health (Larchmt) 2012; 21: 223-230
  9. Poli F., Dreno B., Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001; 15 (6): 541-545.
  10. Mallon E., Newton J.N., Klassen A. et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999; 140 (4): 672-676.
  11. Tan J.K. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Therapy Lett 2004; 9 (7): 1-3, 9
  12. Hirsch R., Shalita A.R. Acne 2002. Cutis 2002; 70 (2): 90.
  13. Rosenfield R.L., Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 1995; 98: 80-88.
  14. Purdy S., De Berker D. Acne. BMJ 2006; 333: 949-953.
  15. Thiboutot D., Gollnick H.P., Bettoli V. et al. New insights into the management of acne: An update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009; 60 (Suppl.5): S.1-S.50.
  16. Lehucher-Ceyrac D., Weber-Buisset M.J. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186: 123-128.
  17. Harms M. Isotretinoin: 10 years on. Dermatology 1993; 186: 81-82.
  18. Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol 2013; 54(3): 157-162.
  19. Nast A., Dreno B., Bettoli V. et al. European evidence-based (S3) guidelines for the treatment of Acne. JEADV 2012; 26 (Suppl. 1): 1-29.
  20. Hull P.R., D’Arcy C. Isotretinoin use and subsequent depression and suicide. Presenting the evidence. Am J Clin Dermatol 2003; 4 (7): 493-505.
  21. Layton A.M., Henderson C.A., Cunliffe W.J. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol 1994; 19: 303-308.
  22. Plewig G., Kligman A.M. Acne and Rosacea. Springer 2000.
  23. Ho V., Schachter D., Miller R. et al. Acne management for the 90s: current treatment guidelines. Cdn J Diagnosis 1995; 12 (Suppl): 1-25.
  24. ICH Guidelines. Good Clin Pract J 1998; 5 (4): 27-37.
  25. Peck G.L., Olsen T.G., Yoder F.W. et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300: 329-333.
  26. Farrell L.N., Strauss J.S., Stranieri A.M. The treatment of severe cystic acne with 13-cis-retinoic acid: Evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol 1980; 3: 602-611.
  27. Jones H., Blanc D., Cunliffe W.J. 13-cis retinoic acid and acne. Lancet 1980; 2: 1048-1049.
  28. King K., Jones D.H., Daltrey D.C., Cunliffe W.J. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982; 107: 583-590.
  29. Jones D.H., King K., Miller A.J., Cunliffe W.J. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108: 333-343.
  30. Stewart M.E., Benoit A.M., Stranieri A.M. et al. Effect of oral 13-cis-retinoic acid at three dose levels on sustainable rates of sebum secretion and on acne. J Am Acad Dermatol 1983; 8: 532-538.
  31. van der Meeren H.L., van der Schroeff J.G., Stijnen T. et al. Dose-response relationship in isotretinoin therapy for conglobate acne. Dermatologica 1983; 167: 299-303.
  32. Al Mishari M.A. A study of isotretinoin (Roaccutan) in nodulocystic acne. Clin Trials J 1986; 23: 1-5.
  33. Goulden V., Stables G.I., Cunliffe W.J. Prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41(4): 577-580.
  34. Ross J.I., Snelling A.M., Carnegie E. et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148 (3): 467-478.
  35. Eady A.E., Cove J.H., Layton A.M. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? : Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003; 4(12): 813-831.
  36. Wessels F., Anderson A.N., Kropman K. The cost-effectiveness of isotretinoin in the treatment of acne. Part 3. A cost-minimisation pharmaco-economic model. S Afr Med J 1999; 89 (7 Pt 2): 791-794
  37. Lee M.L., Cooper A. Isotretinoin: cost-benefit study. Australas J Dermatol 1991; 32 (1): 17-20.
  38. Tan J.K., Tang J., Fung K. et al. Development and validation of a Scale for Acne Scar Severity (SCAR-S) of the face and trunk. J Cutan Med Surg 2010; 14 (4): 156-160.
  39. Hennes R., Mack A., Schell H. et al. 13-cis-retinoic acid in conglobate acne. A follow-up study of 14 trial centers. Arch Dermatol Res 1984; 276: 209-215.
  40. Hermes B., Praetel C., Henz B.M. Medium dose isotretinoin for the treatment of acne. JEADV 1998; 11(2): 117-121.
  41. Agarwal U.S., Besarwal R.K., Bhola K. Oral isotretretinoin in different dose regimens for acne vulgaris: A randomized comparative trial. Indian J Dermatol Venereol Leprol 2011; 77 (6): 688-694.
  42. Nau H. Teratogenicity of isotretinoin revisited: species variation and the role of all-trans-retinoic acid. J Am Acad Dermatol 2001; 45 (5): S183-187.
  43. Creech Kraft J., Lofberg B., Chahoud I. et al. Teratogenicity and placental transfer of all-trans-, 13-cis, 4-oxo-all-trans-, and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice. Toxicol Appl Pharmacol 1989; 100 (1): 162-167.
  44. Mehra Е., Borelli С., Burgdorf W. et al. Treatment of severe acne with low dose of isotretinoin. Acta Derm Venereol 2012; 92: 247-248
  45. Rademaker M., Wishart J.M., Birchall N.M. Isotretinoin 5 mg daily for low-grade adult acne vulgaris - a placebo-controlled, randomized double-blind study. JEADV. 2013 Apr 26. doi: 10.1111/jdv.12170. [Epub ahead of print]
  46. Nelson A.M., Zhao W., Gilliland K.L. et al. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermato-Endocrinology 2009; 1: 3: 177-187
  47. Nelson A.M., Zhao W., Gilliland K.L. et al. Isotretinoin temporally regulates distinct sets of genes in patient skin. J Invest Dermatol 2009; 129: 1038-1042
  48. Zaghloul S.S., Cunliffe W.J., Goodfield M.J. Objective assessment of compliance with treatments in acne. Br J Dermatol 2005; 152 (5): 1015-1021.
  49. Dreno B., Thiboutot D., Gollnick H. et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 2010; 49: 448-456.
  50. Thomas B., Tan J.K. Adherence optimization in acne management. Skin Therapy Letter. FPE. 7-2.1 2011.
  51. Cunliffe W.J., Layton A.M. Oral isotretinoin: patient selection and management. J Dermatol Treatm 1993; 4 (Suppl. 2): S10 - S1S.
  52. Layton A.M., Knaggs H., Taylor J., Cunliffe W.J. Isotretinoin for acne vulgaris-10 years later; a safe and successful treatment. Br J Dermatol 1993; 129 (3): 292-296.
  53. Goulden V., Layton A.M., Cunliffe W.J. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol 1994; 131: 360-363.
  54. Rademaker M. Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol 2010; 51: 248-253.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 KUBANOVA A.A., ARAVIYSKAYA Y.R., SOKOLOVSKY Y.V., DVOROVA Y.K., FADEYEVA Y.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).